Lung cancer is categorized into two types; non-small cell lung cancer (NSCLC) with the 80~85% frequency and small cell lung cancer with the 15~20% frequency. Epidermal growth factor receptor (EGFR) is expressed on the surface of epidermal cells and has the tyrosine kinase activity. Overexpression of EGFR is found only in NSCLC and may lead to signal transduction system in cells by causing cell proliferation, tumor-induced neoangiogenesis (formation of new blood vessels) and transition induction. The EGFR tyrosine kinase inhibitor (TKI), gefinitib (Iressa, AstraZenca) or erlotinib (Tarceba, Roche), is effective to inhibit the growth of cancer cells and leads to death of cancer cells and suppression of new blood vessels in lung cancer tissue. Especially, some specific mutations in the ATP-binding domain of EGFR gene have strong positive correlation with the response rate of EGFR-TKIs. Furthermore, NSCLC patients with the EGFR mutations are reported to be more effective to EGFR-TKI and show prolonged survival rate of patients with lung cancer. Therefore, detection of the EGFR mutation is becoming an important prognostic biomarker for drug response, and efficient detection of the EGFR mutation is expected to be highly helpful for increase of survival rate of patients with lung cancer in targeted therapy.
As this product is Medical Device, please read 'caution' and 'instruction' before use.  
Deliberation number : 2013-I10-11-2363   
Product Name Cat. No. Size
PNAClamp⑩ EGFR Mutation Detection Kit (40 mutations) PNAC-3002 25 tests
No. Reagent Exon Amino Acid Change Nucleotide Change Cosmic No.
1 G719X PNA mix 18 p.G719A C.2156G>C 6239
p.G719S c.2155G>A 6252
p.G719C c.2155G>T 6253
2 E19 del. PNA mix 19 p.E746_A750del c.2235_2249 del 15 6223
p.E746_T751>I c.2235_2252 > AAT 13551
p.E746_T751del c.2236_2253 del 18 12728
p.E746_T751>A c.2237_2251 del 15 12678
p.E746_S752>A c.2237_2254 del 18 12367
p.E746_S752>V c.2237_2255>T 12384
p.E746_A750del c.2236_2250 del 15 6225
p.E746_S752>D c.2238_2255 del 18 6220
p.L747_A750>P c.2238_2248 >GC 12422
p.L747_T751>Q c.2238_2252 >GCA 12419
p.L747_E749del c.2239_2247 del 9 6218
p.L747_T751del c.2239_2253 del 15 6254
p.L747_S752del c.2239_2256 del 18 6255
p.L747_ A750>P c.2239_2248 TTAAGAGAAG>C 12382
p.L747_P753>Q c.2239_2258 >CA 12387
p.L747_T751>S c.2240_2251 del 12 6210
p.L747_P753>S c.2240_2257 del 18 12370
p.L747_T751del c.2240_2254 del 15 12369
p.L747_T751>P c.2239_2251>C 12383
p.E746_A750>IP c.2235_2248>AATTC 13550
p.E746_T751>V c.2237_2252>T 12386
p.E746_T751>IP c.2235_2251>AATTC 13552
p.E746_S752>I c.2235_2255>AAT 12385
p.E746_P753>VS c.2237_2257>TCT 18427
p.L747_T751del c.2238_2252 del 15 23571
p.L747_S752>Q c.2239_2256>CAA 12403
3 T790M PNA mix 20 p.T790M c.2369C>T 6240
4 S768I PNA mix 20 p.S768I c.2303G>T 6241
5 E20 Ins.3dup PNA mix 20 p.H773_V774insH c.2319_2320 insCAC 12377
p.P772_H773insTTP c.2315_2316 insGACAACCCC  
p.P772_H773insGNP c.2315_2316 insGGGCAACCC  
p.H773L c.2318 A>T 13005
p.H773_V774insPH c.2319_2320 insCCCCAC 12380
p.V774_C775insHV c.2321_2322 insCCACGT 18432
6 L858R PNA mix 21 p.L858R c.2573T>G 12429
p.L858R c.2573TG>GT 6224
7 L861Q PNA mix 21 p.L861Q c.2582T>A 6213
Cosmic No. is taken from the Catalogue of Somatic Mutations in Cancer. (http://www.sanger.ac.uk/genetics/CGP/cosmic)
  Ready-to-use kit with result available within 3hours.
  Compatible Real Time PCR
   - ABI 7500, ABI 7900, ABI Step one plus, Bio-Rad CFX96, Light Cycler480 (Roche), Rotor-Gene Q.
  Compatible Sample
   - Fresh tissue, FFPE tissue.
  Test Several Biomarkers in One Plate with same PCR conditions
   - eg. EGFR+KRAS or EGFR+BRAF+PIK3CA in one plate
  High Sensitivity, Specificity with small amount of DNA
As this product is Medical Device, please read 'caution' and 'instruction' before use.  
Deliberation number : 2013-I10-11-2363   
1 Kim et al., Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 2012;75(3):321-325.  
2 Han et al., Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity. J Thorac Oncol. 2012;7(2):355-364.  
3 Choi et al., PNA-mediated Real-Time PCR Clamping for Detection of EGFR Mutations. Bull. Korean Chem. Soc. 2010;31(12):3525-3529.  
4 Lee et al., PNA-Mediated PCR Clamping for the Detection of EGFR Mutations in Non-Small Cell Lung Cancer. Tuberc Respir Dis. 2010;69:271-278.  
5 Noro et al., Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer. 2006;6:277.  
As this product is Medical Device, please read 'caution' and 'instruction' before use.  
Deliberation number : 2013-I10-11-2363